Pfizer's Hympavzi Receives FDA Priority Review for Label Expansion

Pfizer announced that the FDA has granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New York-based pharma giant submitted a supplemental Biologics License Application for the treatment.